Pacira BioSciences Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Pacira BioSciences Inc.
Former names: Pacira Pharmaceuticals, Inc. Pacira Inc Blue Acquisition Corp
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: Brisbane
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: PCRX
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001396814
EIN: 51-0619477

Board of directors

Follow this board

Abraham Ceesay · Director
Since 2023
Alethia Young · Director
Since 2023
Christopher Christie · Director
Since 2023
David M. Stack · Director · CEO and Chairman
Since 2023
Frank D. Lee · Director · Chief Executive Officer
Since 2024
Gary W. Pace · Director
Since 2023
Laura Brege · Director
Since 2023
Marcelo Bigal · Director
Since 2023
Mark A. Kronenfeld · Director
Since 2023
Mark Froimson · Director
Since 2023
Michael J. Yang · Director
Since 2023
Paul J. Hastings · Director
Since 2023
Samit Hirawat · Director
Since 2026
Thomas G. Wiggans · Director
Since 2026

Chief executives

Frank D. Lee · Chief Executive Officer

Since January 2024

32 CEO score

Weak · grade F

Out of 100, from shareholder return, dividends, growth and acquisitions.

Partial: only 35% of the scoring weight is on file.

Revenue growth 20%: 56
Earnings growth 15%: 0

35% of the scoring weight is on file. Figures cover December 2023 – December 2025.

David M. Stack · CEO and Chairman

Until January 2024 · Former

Director election results

Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

8 of this board's directors also sit on 15 other boards. 15 are in the same sector.

Shared director Other board Same sector

ACADIA Pharmaceuticals Inc. Same sector
via Laura Brege
Adial Pharmaceuticals Inc Same sector
via Paul J. Hastings
Annexon Inc. Same sector
via Thomas G. Wiggans
Bausch Health Companies Inc. Same sector
via Frank D. Lee
Bolt Biotherapeutics Inc. Same sector
via Frank D. Lee
Cardiff Oncology Inc. Same sector
via Gary W. Pace
Charles River Laboratories International Inc. Same sector
via Abraham Ceesay
Edgewise Therapeutics Inc. Same sector
via Laura Brege
Ionis Pharmaceuticals Inc. Same sector
via Michael J. Yang
Jasper Therapeutics Inc. Same sector
via Thomas G. Wiggans
Mirum Pharmaceuticals Inc. Same sector
via Laura Brege
Nkarta Inc. Same sector
via Paul J. Hastings
PTC Therapeutics Inc. Same sector
via Alethia Young
Rapport Therapeutics Inc. Same sector
via Abraham Ceesay
enGene Therapeutics Inc. Same sector
via Paul J. Hastings

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $2,483,639; 16 sales by 5 insiders

Date	Insider	Transaction	Shares	Price	Value
Oct 30, 2026	Cross Shawn Officer (Chief Financial Officer)	Shares withheld for tax	−9,540	$36.39	$347,161
Oct 8, 2026	RIKER LAUREN Officer (Senior Vice President, Finance)	Option exercise	+6,000	$32.35	$194,100
Oct 8, 2026	RIKER LAUREN Officer (Senior Vice President, Finance)	Open-market sale	−6,000	$36.32	$217,920
Aug 17, 2026	SLONIN JONATHAN Officer (Chief Medical Officer)	Open-market sale	−3,040	$23.23	$70,619
Jun 11, 2026	RIKER LAUREN Officer (Senior Vice President, Finance)	Open-market sale	−6,115	$23.50	$143,703
Jun 10, 2026	Samit Hirawat Director	Grant or award	+6,405	—	—
Jun 10, 2026	Christopher Christie Director	Grant or award	+6,405	—	—
Jun 10, 2026	Alethia Young Director	Grant or award	+6,405	—	—
Jun 10, 2026	Michael J. Yang Director	Grant or award	+6,405	—	—
Jun 10, 2026	Marcelo Bigal Director	Grant or award	+6,405	—	—
Jun 10, 2026	Mark Froimson Director	Grant or award	+6,405	—	—
Jun 10, 2026	Laura Brege Director	Grant or award	+6,405	—	—
Jun 4, 2026	WILLIAMS KRISTEN Officer (Chief Administrative Officer)	Open-market sale	−10,259	$22.27	$228,468
Jun 3, 2026	RIKER LAUREN Officer (Senior Vice President, Finance)	Shares withheld for tax	−3,187	$22.32	$71,134
Jun 3, 2026	SLONIN JONATHAN Officer (Chief Medical Officer)	Shares withheld for tax	−4,728	$22.32	$105,529

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Pacira BioSciences Inc.

Who is the CEO of Pacira BioSciences Inc.?

Frank D. Lee has been Pacira BioSciences Inc.'s Chief Executive Officer since January 2024.

How many directors are on Pacira BioSciences Inc.'s board?

Pacira BioSciences Inc.'s board has 14 directors: Abraham Ceesay, Alethia Young, Christopher Christie, David M. Stack, Frank D. Lee, Gary W. Pace, Laura Brege, Marcelo Bigal, Mark A. Kronenfeld, Mark Froimson and 4 others.

Are Pacira BioSciences Inc. insiders buying or selling shares?

Over the last 12 months, Pacira BioSciences Inc. insiders made no open-market purchases and sold $2.5 million of shares in 16 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Pacira BioSciences Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="pacira-biosciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.